<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">A doctor from France cited four cases of young patients with COVID-19 and no underlying health problems who went on to develop serious symptoms after using non-steroidal anti-inflammatory drugs (NSAIDs) in the early stage of disease. This observation prompted the advice against the use of ibuprofen in this condition [
 <xref rid="bib17" ref-type="bibr">17</xref>]. World Health Organisation (WHO) first recommended against using ibuprofen in COVID-19, however went back against its own advice and updated its advice soon to say that “based on currently available information, WHO does not recommend against the use of ibuprofen” [
 <xref rid="bib18" ref-type="bibr">18</xref>]. It is interesting to note that several previous studies have shown a complicated course with increased incidence of empyema, lung cavitation and prolonged stay in the intensive care unit when nonsteroidal anti-inflammatory drugs (NSAIDs) were used in patients with pneumonia [
 <xref rid="bib19" ref-type="bibr">19</xref>].
</p>
